Zentalis Pharmaceuticals, Inc.
ZNTL
$1.43
-$0.08-5.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -55.90% | 27.68% | 21.55% | 115.93% | -10.82% |
| Total Depreciation and Amortization | -5.93% | -7.76% | -4.94% | -10.00% | -6.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 199.45% | -74.01% | 1.68% | -361.78% | -26.97% |
| Change in Net Operating Assets | -168.91% | -251.87% | 373.02% | -305.70% | 157.80% |
| Cash from Operations | 2.21% | -13.91% | 55.67% | -5.46% | -8.76% |
| Capital Expenditure | 100.00% | 100.00% | 43.26% | -- | -8.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 177.07% | 141.11% | -52.76% | 46.21% | -256.97% |
| Cash from Investing | 176.75% | 141.08% | -52.71% | 46.11% | -253.62% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -70.23% | -100.00% | -33.51% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -70.23% | -100.00% | -98.12% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 91.02% | 102.75% | -100.28% | 241.08% | -16,057.34% |